Kymera Therapeutics, Inc. (KYMR) Cash Flow Statement
Kymera Therapeutics, Inc. (KYMR) generated -$236.8M of operating cash flow over the twelve months to 2026-06-30, spent $1.2M on capital expenditure and had free cash flow of -$238.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KYMRKymera Therapeutics, Inc.Follow KYMR — free
—
Price chart with a free account
- Market cap
- 9.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.09 | -0.13 | -0.15 | -0.10 | -0.19 | -0.23 | -0.24 | |
| Capital expenditure | 0.01 | 0.00 | 0.00 | 0.03 | 0.01 | 0.00 | -0.00 | |
| Free cash flow | 0.08 | -0.13 | -0.16 | -0.14 | -0.21 | -0.23 | -0.24 | |
| Stock-based compensation | 0.01 | 0.02 | 0.04 | 0.04 | 0.06 | 0.06 | — |
USD billions · SEC XBRL
Kymera Therapeutics, Inc. — questions
- What is Kymera Therapeutics, Inc.'s operating cash flow?
- -$236.8M over the twelve months to 2026-06-30.
- How much does Kymera Therapeutics, Inc. spend on capital expenditure?
- $1.2M over the twelve months to 2026-06-30.
- What is Kymera Therapeutics, Inc.'s free cash flow?
- -$238.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Kymera Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.